Technology Bundle ID
TAB-3370

Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane

Linked ID
E-185-2018-0
Lead Inventors
Paolo Lusso (NIAID)
Co-Inventors
Peng Zhang (NIAID)
ICs
Transduced human cell lines expressing high levels of native HIV-1 Envelope on their surface membrane, in the unmodified or interdomain stabilized form. These cell lines provide a stable source of native HIV-1 envelope for multiple uses, including the high-efficiency production of virus-like particles (VLPs) for use as vaccines, testing new inhibitors or neutralizing antibodies, or identifying/capturing B cells that produce broadly neutralizing antibodies from infected/vaccinated humans or animals.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
Commercial Applications
  • High-efficiency production of virus-like particles (VLPs)
  • A means to test new inhibitors or neutralizing antibodies targeting HIV-1 envelope trimers
  • Probe for identifying/capturing B cells that produce broadly neutralizing antibodies
Competitive Advantages
  • The interdomain-stabilized form does not bind CD4 and is locked in the native prefusion form

Request More Info

Licensing Contact: